You are seeing this message because your Web browser does not support basic Web standards. Find out more about why this message is appearing and what you can do to make your experience on this site better.


ABOUT ARCHIVES
Advanced Search

Welcome   | My Account | E-mail Alerts | Access Rights | Sign In


  Vol. 126 No. 10, October 2008 TABLE OF CONTENTS
  Archives
  •  Online Features
  Clinical Trial
 This Article
 •Full text
 •PDF
 •eTable and eFigure
 • Reply to article
 •Send to a friend
 • Save in My Folder
 •Save to citation manager
 •Permissions
 Citing Articles
 •Citation map
 •Citing articles on HighWire
 •Contact me when this article is cited
 Related Content
 •Related letters
 •Related articles
 •Similar articles in this journal
 Topic Collections
 •Pediatric Ophthalmology
 •Ophthalmological Disorders, Other
 •Pediatrics
 •Pediatrics, Other
 •Randomized Controlled Trial
 •Alert me on articles by topic
 Social Bookmarking
  Add to CiteULike Add to Connotea Add to Del.icio.us Add to Digg Add to Reddit Add to Technorati Add to Twitter What's this?

Randomized Clinical Trial of Treatments for Symptomatic Convergence Insufficiency in Children

Convergence Insufficiency Treatment Trial Study Group*

Arch Ophthalmol. 2008;126(10):1336-1349.

Objective  To compare home-based pencil push-ups (HBPP), home-based computer vergence/accommodative therapy and pencil push-ups (HBCVAT+), office-based vergence/accommodative therapy with home reinforcement (OBVAT), and office-based placebo therapy with home reinforcement (OBPT) as treatments for symptomatic convergence insufficiency.

Methods  In a randomized clinical trial, 221 children aged 9 to 17 years with symptomatic convergence insufficiency were assigned to 1 of 4 treatments.

Main Outcome Measures  Convergence Insufficiency Symptom Survey score after 12 weeks of treatment. Secondary outcomes were near point of convergence and positive fusional vergence at near.

Results  After 12 weeks of treatment, the OBVAT group's mean Convergence Insufficiency Symptom Survey score (15.1) was statistically significantly lower than those of 21.3, 24.7, and 21.9 in the HBCVAT+, HBPP, and OBPT groups, respectively (P < .001). The OBVAT group also demonstrated a significantly improved near point of convergence and positive fusional vergence at near compared with the other groups (P ≤ .005 for all comparisons). A successful or improved outcome was found in 73%, 43%, 33%, and 35% of patients in the OBVAT, HBPP, HBCVAT+, and OBPT groups, respectively.

Conclusions  Twelve weeks of OBVAT results in a significantly greater improvement in symptoms and clinical measures of near point of convergence and positive fusional vergence and a greater percentage of patients reaching the predetermined criteria of success compared with HBPP, HBCVAT+, and OBPT.

Application to Clinical Practice  Office-based vergence accommodative therapy is an effective treatment for children with symptomatic convergence insufficiency.

Trial Registration  clinicaltrials.gov Identifier: NCT00338611



*Authors/Writing Committee: The following members of the Convergence Insufficiency Treatment Trial Study Group take authorship responsibility for the results: Lead authors: Mitchell Scheiman, OD; Susan Cotter, OD, MS; G. Lynn Mitchell, MAS; Marjean Kulp, OD, MS; Michael Rouse, OD, MEd; Richard Hertle, MD; and Maryann Redford, DDS, MPH. Additional writing committee members (alphabetical): Jeffrey Cooper, MS, OD; Rachel Coulter, OD; Michael Gallaway, OD; David Granet, MD; Kristine Hopkins, OD, MSPH; Brian G. Mohney, MD; and Susanna Tamkins, OD.



Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter     What's this?

RELATED LETTERS

Evisceration of Blind, Painful Eyes With Occult Uveal Melanoma Not a Crime—Reply
Ralph C. Eagle, Jr, Hans E. Grossniklaus, Nasreen A. Syed, R. Nick Hogan, William C. Lloyd, III, and Robert Folberg
Arch Ophthalmol. 2009;127(9):1229.
EXTRACT | FULL TEXT  

The Steroid Controversy in Bacterial Keratitis
Nisha R. Acharya, Muthiah Srinivasan, Jeena Mascarenhas, Meenakshi Ravindran, Revathi Rajaraman, Michael Zegans, Stephen McLeod, and Thomas M. Lietman
Arch Ophthalmol. 2009;127(9):1231.
EXTRACT | FULL TEXT  

RELATED ARTICLES

Response to Editorial About the Convergence Insufficiency Treatment Trial
Susan Cotter, Marjean Kulp, Mitchell Scheiman, Richard Hertle, G. Lynn Mitchell, Michael Rouse, and for the Convergence Insufficiency Treatment Trial (CITT) Executive Committee
Arch Ophthalmol. 2009;127(9):1229-1230.
EXTRACT | FULL TEXT  

Treatment Options for Symptomatic Convergence Insufficiency
David K. Wallace
Arch Ophthalmol. 2008;126(10):1455-1456.
EXTRACT | FULL TEXT  


THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Response to Editorial About the Convergence Insufficiency Treatment Trial--Reply
Wallace
Arch Ophthalmol 2009;127:1230-1231.
FULL TEXT  

Response to Editorial About the Convergence Insufficiency Treatment Trial
Cotter et al.
Arch Ophthalmol 2009;127:1229-1230.
FULL TEXT  

Learning Disabilities, Dyslexia, and Vision
American Academy of Pediatrics, Section on Ophthal et al.
Pediatrics 2009;124:837-844.
ABSTRACT | FULL TEXT  

Effectiveness of Placebo Therapy for Maintaining Masking in a Clinical Trial of Vergence/Accommodative Therapy
Kulp et al.
IOVS 2009;50:2560-2566.
ABSTRACT | FULL TEXT  

Does Nonsurgical Treatment of Exodeviations Work?
Karlsson
Amer. Orthoptic Jrnl. 2009;59:18-25.
ABSTRACT  

Treatment Options for Symptomatic Convergence Insufficiency
Wallace
Arch Ophthalmol 2008;126:1455-1456.
FULL TEXT  





HOME | CURRENT ISSUE | PAST ISSUES | TOPIC COLLECTIONS | CME | SUBMIT | SUBSCRIBE | HELP
CONDITIONS OF USE | PRIVACY POLICY | CONTACT US | SITE MAP
 
© 2008 American Medical Association. All Rights Reserved.